Co-Diagnostics, Inc. reported a significant decline in financial performance for the third quarter of 2025, with total revenue of $145,380, a decrease of approximately 77% compared to $641,141 in the same period of 2024. For the nine months ending September 30, 2025, total revenue was $358,567, down from $3,765,835 in the prior year. The company attributed this decline primarily to the absence of grant revenue, which had contributed $434,265 in Q3 2024 and $3,145,112 in the first nine months of that year. Product revenue also fell, with $145,380 reported for Q3 2025 compared to $206,876 in Q3 2024.
The company's net loss for the third quarter of 2025 was $5,886,823, or $(0.16) per share, an improvement from a net loss of $9,696,455, or $(0.32) per share, in the same quarter of the previous year. For the nine-month period, the net loss was $21,150,211, compared to $26,607,816 in 2024. Operating expenses decreased to $7,132,943 in Q3 2025 from $10,578,675 in Q3 2024, reflecting cost-cutting measures. The company’s cash and cash equivalents increased to $11,443,943 as of September 30, 2025, up from $2,936,544 at the end of 2024.
In terms of strategic developments, Co-Diagnostics has been active in capital raising efforts. The company completed a registered direct offering on September 18, 2025, raising approximately $3.8 million by issuing 9,619,000 shares at $0.40 each. Additionally, on October 20, 2025, Co-Diagnostics entered into a new equity distribution agreement with Maxim Group LLC, allowing for the potential sale of up to $10 million in common stock. These initiatives are part of the company's strategy to secure necessary financing to support operations and growth.
Operationally, the company reported a decrease in customer engagement, with product revenue from the United States accounting for 94% of total revenue in Q3 2025, compared to 88% in Q3 2024. The company’s total assets decreased to $44,740,761 as of September 30, 2025, down from $63,999,919 at the end of 2024, primarily due to reduced cash reserves and marketable securities. The company’s employee headcount remained stable, with no significant changes reported.
Looking ahead, Co-Diagnostics expressed uncertainty regarding its ability to continue as a going concern, emphasizing the need for additional financing to meet operational obligations. The company plans to pursue equity financing and operational efficiencies to address its capital requirements. Management noted that while they are optimistic about future product development and market opportunities, the ability to raise sufficient capital remains a critical factor for the company's sustainability.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. develops and manufactures molecular diagnostic tests using proprietary PCR technology to detect infectious diseases and genetic traits. Its core products include PCR-based diagnostic kits for COVID-19, influenza, tuberculosis, HPV, and other pathogens, sold globally to clinical labs and health agencies. The company emphasizes affordable, rapid, and accurate testing solutions, with a focus on innovative platform development for point-of-care and at-home use.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.